Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

Paul S. Teirstein, Ian T. Meredith, Robert L. Feldman, A. Charles Rabinowitz, Louis A. Cannon, Tommy C. Lee, Joseph Dens, Christophe L. Dubois, Michael R. Mooney, Vincent J Pompili, Shigeru Saito, Dominic J. Allocco, Keith D. Dawkins, Gregg W. Stone

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background: Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods: The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≤2.25 mm to <2.50 mm in diameter and & ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to & ≤34 mm long in vessels ≤2.50 to & ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results: One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up. Conclusions: The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.

Original languageEnglish (US)
Pages (from-to)207-215
Number of pages9
JournalCatheterization and Cardiovascular Interventions
Volume85
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Chromium
Platinum
Stents
Safety
AIDS-Related Complex
Therapeutics
Drug-Eluting Stents
Paclitaxel
Coronary Vessels
Thrombosis
Myocardial Infarction
Everolimus

Keywords

  • Coronary stenosis
  • Drug-eluting
  • Everolimus
  • Randomized controlled trial
  • Stents

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. / Teirstein, Paul S.; Meredith, Ian T.; Feldman, Robert L.; Rabinowitz, A. Charles; Cannon, Louis A.; Lee, Tommy C.; Dens, Joseph; Dubois, Christophe L.; Mooney, Michael R.; Pompili, Vincent J; Saito, Shigeru; Allocco, Dominic J.; Dawkins, Keith D.; Stone, Gregg W.

In: Catheterization and Cardiovascular Interventions, Vol. 85, No. 2, 01.02.2015, p. 207-215.

Research output: Contribution to journalArticle

Teirstein, PS, Meredith, IT, Feldman, RL, Rabinowitz, AC, Cannon, LA, Lee, TC, Dens, J, Dubois, CL, Mooney, MR, Pompili, VJ, Saito, S, Allocco, DJ, Dawkins, KD & Stone, GW 2015, 'Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions', Catheterization and Cardiovascular Interventions, vol. 85, no. 2, pp. 207-215. https://doi.org/10.1002/ccd.25565
Teirstein, Paul S. ; Meredith, Ian T. ; Feldman, Robert L. ; Rabinowitz, A. Charles ; Cannon, Louis A. ; Lee, Tommy C. ; Dens, Joseph ; Dubois, Christophe L. ; Mooney, Michael R. ; Pompili, Vincent J ; Saito, Shigeru ; Allocco, Dominic J. ; Dawkins, Keith D. ; Stone, Gregg W. / Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. In: Catheterization and Cardiovascular Interventions. 2015 ; Vol. 85, No. 2. pp. 207-215.
@article{da082456a573488ca52b75729e4a3eb1,
title = "Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions",
abstract = "Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background: Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods: The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≤2.25 mm to <2.50 mm in diameter and & ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to & ≤34 mm long in vessels ≤2.50 to & ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results: One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4{\%} versus 21.1{\%} in the SV cohort and 3.2{\%} versus 19.4{\%} in the LL cohort. Cumulative rates of TLF to 2 years were 4.7{\%} in the SV cohort and 8.8{\%} in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up. Conclusions: The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.",
keywords = "Coronary stenosis, Drug-eluting, Everolimus, Randomized controlled trial, Stents",
author = "Teirstein, {Paul S.} and Meredith, {Ian T.} and Feldman, {Robert L.} and Rabinowitz, {A. Charles} and Cannon, {Louis A.} and Lee, {Tommy C.} and Joseph Dens and Dubois, {Christophe L.} and Mooney, {Michael R.} and Pompili, {Vincent J} and Shigeru Saito and Allocco, {Dominic J.} and Dawkins, {Keith D.} and Stone, {Gregg W.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/ccd.25565",
language = "English (US)",
volume = "85",
pages = "207--215",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

AU - Teirstein, Paul S.

AU - Meredith, Ian T.

AU - Feldman, Robert L.

AU - Rabinowitz, A. Charles

AU - Cannon, Louis A.

AU - Lee, Tommy C.

AU - Dens, Joseph

AU - Dubois, Christophe L.

AU - Mooney, Michael R.

AU - Pompili, Vincent J

AU - Saito, Shigeru

AU - Allocco, Dominic J.

AU - Dawkins, Keith D.

AU - Stone, Gregg W.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background: Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods: The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≤2.25 mm to <2.50 mm in diameter and & ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to & ≤34 mm long in vessels ≤2.50 to & ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results: One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up. Conclusions: The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.

AB - Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background: Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods: The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≤2.25 mm to <2.50 mm in diameter and & ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to & ≤34 mm long in vessels ≤2.50 to & ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results: One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up. Conclusions: The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.

KW - Coronary stenosis

KW - Drug-eluting

KW - Everolimus

KW - Randomized controlled trial

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=84922062184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922062184&partnerID=8YFLogxK

U2 - 10.1002/ccd.25565

DO - 10.1002/ccd.25565

M3 - Article

VL - 85

SP - 207

EP - 215

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -